Date: 2015-09-29
Type of information: Initiation of the trial
phase: 2-3
Announcement: initiation of the trial
Company: Novartis Pharmaceuticals (Switzerland) Banner Alzheimer\'s Institute (USA - Denmark) National Institute on Aging (NIA) (USA) Alzheimer\'s Association (USA)
Product: CAD106 and CNP520
Action
mechanism: immunotherapy product/peptide/enzyme inhibitor/BACE (beta-site APP-cleaving enzyme-1) inhibitor. CNP520 is a BACE (beta-site APP-cleaving enzyme-1) inhibitor. This oral drug has been designed to prevent the production of different forms of amyloid and has the potential to prevent, slow or delay the symptoms associated with Alzheimer\'s disease. It is currently in Phase 1/2a trials. BACE (beta-site APP-cleaving enzyme-1) initiates the production of beta amyloid (Ab), the primary constituent of amyloid plaques that are believed to play a key role in the etiology of Alzheimer\'s disease. It is hypothesized that inhibiting BACE could reduce the production of amyloid plaques. Amgen was the first to clone and characterize BACE in a 1999 Science publication. Amgen subsidiary deCODE Genetics subsequently added corroborating human genetic evidence of its link to Alzheimer\'s disease in a 2012 Nature publication. CAD106 combines multiple copies of Aβ1-6 peptide derived from the N-terminal B cell epitope of Aβ, coupled to a Qβ virus-like particle. In animals, CAD106 induced Aβ-antibody titers without activating Aβ-reactive T cells. In July 2014, Novartis and Banner Alzheimer's Institute (BAI) have announced a collaboration on a pioneering clinical study in Alzheimer's disease (AD) prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease.
Disease: Alzheimer's disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial
details: The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer\'s disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. (NCT02565511) This phase 2/3 trial is set to run from November 2015.
Latest news:
